Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1991-6-26
|
| pubmed:abstractText |
Small-noncleaved-cell (SNC) lymphoma is a high-grade, biologically aggressive neoplasm notable for poor response to therapy, high relapse rate, and less than a 20% long-term survival. We treated 20 patients with SNC lymphoma with a novel chemotherapeutic regimen using intensive doses of chemotherapy at frequent intervals in the inpatient setting. All patients were previously untreated. Sixteen patients (80%) had stage IV disease. Most patients (95%) had at least one other characteristic associated with poor prognosis (bulky [greater than 10 cm] disease, multiple extranodal sites, poor performance status), and 85% had two or more characteristics associated with poor prognosis. Seventeen patients (85%) achieved a complete response (CR) to therapy, including all three patients with human immunodeficiency virus (HIV)-associated disease. There have been three relapses, all occurring less than 18 months after treatment, and two of three relapses occurred in patients who were unable to complete therapy. At a median follow-up of 29 months, 13 patients (65%) remain disease-free; the calculated 5-year actuarial disease-free survival is 60%. Toxicity, chiefly myelosuppression, was severe but manageable. There were two treatment-related deaths, both in elderly patients with poor performance status and advanced-stage disease. These data suggest that such a dose-intensive approach improves the response and survival of patients with SNC lymphoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
941-6
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1709685-Adult,
pubmed-meshheading:1709685-Aged,
pubmed-meshheading:1709685-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1709685-Bleomycin,
pubmed-meshheading:1709685-Cyclophosphamide,
pubmed-meshheading:1709685-Doxorubicin,
pubmed-meshheading:1709685-Etoposide,
pubmed-meshheading:1709685-Female,
pubmed-meshheading:1709685-Follow-Up Studies,
pubmed-meshheading:1709685-Hematologic Diseases,
pubmed-meshheading:1709685-Humans,
pubmed-meshheading:1709685-Leucovorin,
pubmed-meshheading:1709685-Lymphoma, Non-Hodgkin,
pubmed-meshheading:1709685-Male,
pubmed-meshheading:1709685-Methotrexate,
pubmed-meshheading:1709685-Middle Aged,
pubmed-meshheading:1709685-Neoplasm Staging,
pubmed-meshheading:1709685-Prednisone,
pubmed-meshheading:1709685-Prognosis,
pubmed-meshheading:1709685-Survival Rate,
pubmed-meshheading:1709685-Vincristine
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy.
|
| pubmed:affiliation |
Division of Medical Oncology, Vanderbilt University, Nashville, TN.
|
| pubmed:publicationType |
Journal Article
|